The global hepatitis A vaccines market size was valued at USD 1.24 billion in 2024 and is projected to grow from USD 1.26 billion in 2025 to USD 2.57 billion by 2032, exhibiting a CAGR of 10.7% during the forecast period. North America dominated the hepatitis A vaccines market with a 50% share in 2024, driven by strong immunization programs, high awareness levels, and supportive government initiatives for preventive healthcare.